A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
A phase 2 trial of Pembrolizumab in melanoma, run by Evaxion Biotech A/S, active and no longer recruiting.
Overview
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma is a phase 2 interventional study registered as NCT05309421 by Evaxion Biotech A/S, with 17 participants enrolled, started 2022-09-19 and due to reach its primary completion in 2025-09-30. Interventions recorded: EVX-01, Pembrolizumab 25 MG/ML. Conditions listed: Melanoma Stage IV, Unresectable Melanoma. No results are recorded here; the registry entry is the source.
Setting
An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma
Phase
Phase 2
Sponsor
Evaxion Biotech A/S
Registry
Enrolled
17